(OTCBB:NNVC) NanoViricides, Inc

Turning Pennies into dollars: (OTCBB:NNVC) NanoViricides, Inc

Are you a public company looking for exposure?

Contact RealPennies.com - 212-662-2147

For more info: http://www.realpennies.com/otc/nnvc

NanoViricides, Inc. Update on Eye Drug Development

(OTCBB:NNVC) NanoViricides, Inc.

NanoViricides, Inc. Update on Eye Drug Development

Monday February 9, 7:00 am ET

WEST HAVEN, Conn.-NanoViricides, Inc. , reported recently that on-going negotiations with a large pharmaceutical company have now progressed to an advanced stage. The pharmaceutical company initially plans to evaluate NanoViricides?s drug candidate for effectiveness against external ophthalmic diseases caused by two different virus types, namely herpes simplex virus and adenovirus. These evaluations will be performed by an independent research institute that specializes in diseases of the eye.

HSV and some adenoviruses cause most of the cases of keratitis, a serious infection of the cornea. Importantly, HSV infection can lead to corneal scarring that may necessitate corneal transplantation. In addition, some adenoviruses cause a majority of conjunctivitis cases . The remaining cases of conjunctivitis, caused by bacteria, are treatable with topical antibiotics. Currently, there are no effective treatments for viral diseases of the exterior portion of the eye.

The Company has already demonstrated strong efficacy against an adenovirus-caused external eye disease called epidemic kerato-conjunctivitis . Rapid clinical improvement in the treated animals was reported by independent researchers who tested the effects of the nanoviricides drug candidate against adenoviral EKC. Based on computer modeling, the Company believes that the broad-spectrum nature of the ligand used in this nanoviricide should enable it to be effective against HSV.

The total market for viral conjunctivitis is estimated to be in the billions of dollars. The incidence of severe herpes keratitis is estimated to be 250,000 cases per year in the USA. In Japan, where EKC is a reportable disease, it is estimated that there are at least one million cases per year. The number of cases of non-specific conjunctivitis is considered to be far greater, possibly into tens of millions in the US, and into hundreds of millions worldwide.

The Company will need to procure large quantities of the nanoviricides drug candidates for the upcoming studies. In order to support this production scale, TheraCour Pharma, Inc., the Company?s largest shareholder and licensor of the technology that the Company uses in its anti-viral drug development, has initiated a program to expand its laboratory facilities. TheraCour has entered into a Rule 10b5-1 trading plan to sell, over a one year period, up to 1.8 million shares of the Company?s common stock that it owns. The proceeds are to be used to pay for the necessary improvements in laboratory facilities, the purchase of analytical equipment, and the costs of intellectual property protection.

?NanoViricides will benefit from the advanced instrumentation that TheraCour plans to purchase without having to make the capital expenditure itself,? said Eugene Seymour, MD, MPH, CEO of NanoViricides, adding, ?Availability of larger quantities of our drug candidates will greatly expedite our drug development for a number of different viral diseases. This should accelerate our efforts to move our drugs into the FDA approval process.?

About NanoViricides:

NanoViricides, Inc. is a development stage company that is creating special purpose nanomaterials for viral therapy. The Company's novel nanoviricide? class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H5N1 bird flu, seasonal Influenza, HIV, EKC, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others.

This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are ?forward-looking statements? within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in pre-clinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.

Contact:

NanoViricides, Inc. Amanda Schuon, 310-550-7200 info@nanoviricides.com Source: NanoViricides, Inc.

Profile for NanoViricides, Inc.

NanoViricides, Inc., a development stage nano-biopharmaceutical company, engages in the discovery, development, and commercialization of anti-viral therapeutics primarily in the United States. It has licenses in perpetuity to develop drugs for the treatment of human viral diseases, such as human immunodeficiency virus, Hepatitis B Virus, Hepatitis C Virus , Herpes Simplex Virus, Rabies, Influenza, and Asian Bird Flu Virus. The company’s products under development include FluCide-I for the treatment of common influenzas and avian influenza H5N1; AviFluCide-I against H5N1, the avian influenza strain; FluCide-HP against highly pathogenic avian influenza viruses; RabiCide-I, a nanoviricide ... Detailed NNVC Company Description...

LAST $0.70 USD

Find out more about NNVC

Realpennies.com

Investors are advised that this analysis is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy. This report does not have regard to the specific investment objectives, financial situation and the particular needs of any specific person who may receive this information. The information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Past performance is no guarantee of future results. Please consult a broker before purchasing or selling any securities mentioned on

http://www.realpennies.com/start.html

Any opinions expressed herein are statements of our judgment as of the date of publication and are subject to change without notice. This may contain forward-looking statements and are not guarantees of performance. Reproduction of this without written permission is prohibited.

RealPennies.com

Phone: 212-662-2147

info [at] realpennies.com